Allergan rose$. 01 or percent, to $101.49. Baxter International Inc. rose$. 15 or. 2 percent, to $70.88. Boston Scientific Corp. fell$. 10 or 1.0 percent, to $9.54.» Read More
Los Angeles, Jan 25- Johnson& Johnson was aware of defects when it started selling its now-recalled metal hip implants in 2004, lawyers said on Friday during opening arguments in a personal injury trial against the company. The suit was filed in California Superior Court by 66- year-old Loren Kransky, whose ASR hip was replaced early last year.
*4th- qtr profit 89 cents/ share vs 82 cents a year ago. Jan 24- Medical device and bioscience company Baxter International Inc reported higher quarterly earnings on Thursday and forecast sales growth of 10 percent for 2013..
*Profit ex-items of $1.14/ shr tops estimates by 2 cts. *Continues to see 2013 earnings of $4.25 to $4.40 a share. Jan 23- U.S. orthopedic implant maker Stryker Corp on Wednesday reported fourth-quarter earnings excluding charges that exceeded analyst estimates as sales of its hip, knee and spine products improved.
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
Jan 18- Johnson& Johnson is negotiating a potential $2 billion settlement with patients who received its recalled artificial hip implant, Bloomberg News reported on Friday, citing five people familiar with the matter.
Jan 17- Medical device maker Stryker Corp said it will buy Hong Kong- based Trauson Holdings Co Ltd for $764 million in cash to expand in China, one of the fastest-growing markets for orthopaedic products. Founded in China in 1986, orthopaedics firm Trauson had sales of about $60 million in 2011 and makes spine devices and products for trauma surgeries.
Jan 17- Medical device maker Stryker Corp said it will buy Hong Kong- based Trauson Holdings Co Ltd for $764 million in an all cash deal, to expand in one of the fastest-growing markets for orthopaedic products in China. Stryker will pay HK $7.50 for every share of Trauson.
"Providers whose advertising does not provide adequate risk information are finding out today that the FDA is serious about consumer protection," said Steve Silverman, compliance director at FDA's Center for Devices and Radiological Health in a statement posted on the agency's website.
DaVita could be a beneficiary among health care stocks from changes in the U.S. health care market, an analyst said Wednesday.
It was a complicated case, in part because the reform legislation itself was seriously flawed. The law’s drafters could have proposed a simpler and more efficient system, the New York Times reports.
While some people are frustrated about the long wait times for doctors appointments, some believe doctors are doing their jobs.
Ronald Ennis, M.D., St. Luke's/Roosevelt director of Radiation Oncology, Sally Pipes, Pacific Research Institute President & CEO, provide insight on paying for pricey drugs and medical treatment.
Discussing an innovative approach to keeping fit, with Christine Robins, CEO of BodyMedia, which makes wearable body monitoring devices designed to help people lead healthier lives.
American spends more on health care than any other country. Do you know where it goes?
Discussing earnings and long term growth, with Kieran Gallahue, CareFusion Corporation chairman & CEO.
Over the last 20 years, Americans have witnessed unprecedented advances in care of hospitalized patients. Improved diagnostic procedures, quantum leaps in medical technology, enhanced treatments and a public now familiar with the concept of preventative medical care all mean that healthcare – especially in the hospital – has changed to meet the health care needs of today’s patients.
With stocks shrugging off the wall of worry in the first quarter, the second quarter could prove to be a less rewarding time for those long equity markets as central banks begin to tighten policy via rate hikes or withdrawing extraordinary measures.
The "Mad Money" host shares a few interesting spec plays in the health care space.